C-Path starts DMD consortium

The Critical Path Institute formed the Duchenne Regulatory Sciences Consortium (D-RSC) with founding members Santhera Pharmaceuticals Holding AG (SIX:SANN); PTC Therapeutics Inc. (NASDAQ:PTCT); and Brenda Wong of Cincinnati Children's Hospital Medical Center. C-Path said additional members will be added to the consortium soon, including Sarepta Therapeutics Inc. (NASDAQ:SRPT), with which it is negotiating a final agreement.

C-Path said that the D-RSC will initially focus on building a disease progression model for DMD, and will seek U.S. and EU endorsement for new drug development tools. ...